爱尔兰2型糖尿病队列中风险预测模型预测转诊糖尿病视网膜病变进展的性能检验
本研究利用爱尔兰939例2型糖尿病前瞻性队列数据,评估英国Gloucester和冰岛开发的现有风险预测模型预测转诊糖尿病视网膜病变(RDR)进展的性能。队列随访2929人年、2906次筛查,共40例(4%)转诊。各模型AUC为0.69至0.77,判别力可接受,有助于制定个性化筛查间隔。
要点
- 在爱尔兰2型糖尿病队列中,测试的预测模型对RDR进展具有可接受的判别性能。
- Gloucester原始模型AUC为0.69,加入系统生物标志物后AUC为0.76,另一模型AUC为0.77。
- 冰岛模型AUC为0.74,性能与Gloucester模型相似。
核心结论
- 在爱尔兰2型糖尿病队列中,所测试的风险预测模型识别RDR进展风险的性能可接受。
- 这些风险模型有助于为2型糖尿病患者建立更个性化的筛查间隔。
研究设计与样本
- 采用前瞻性队列研究,纳入939例爱尔兰2型糖尿病患者。
- 队列随访共2929人年,期间发生2906次筛查。
- 评估英国Gloucester和冰岛开发的现有风险预测模型预测RDR进展的性能。
- 比较爱尔兰队列观察到的RDR进展风险与各预测模型得出的风险。
- 使用受试者工作特征曲线评估模型性能。
主要发现
- 939例随访个体中,40例(4%)因糖尿病黄斑病变、增殖前期DR和增殖性DR转诊。
- Gloucester原始模型(含连续两次视网膜筛查结果)AUC为0.69。
- 额外纳入系统生物标志物(HbA1c和血清胆固醇)的模型AUC为0.76。
- 纳入一次视网膜病变筛查结果、HbA1c、总胆固醇和糖尿病病程的模型AUC为0.77。
- 冰岛模型(结合视网膜病变分级、糖尿病病程和类型、HbA1c和收缩压)AUC为0.74。
关键数值与推荐
- Gloucester原始模型AUC为0.69,判别力可接受。
- Gloucester模型加入HbA1c和血清胆固醇后AUC为0.76。
- 纳入一次筛查结果、HbA1c、总胆固醇和糖尿病病程的模型AUC为0.77。
- 冰岛模型AUC为0.74,性能与Gloucester模型非常相似。
临床怎么用
- 可将验证的预测模型用于2型糖尿病患者RDR进展风险评估。
- 基于风险预测结果可考虑制定更个性化的视网膜病变筛查间隔。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND /AIMS: To evaluate the performance of existing prediction models to determine risk of progression to referable diabetic retinopathy (RDR) using data from a prospective Irish cohort of people with type 2 diabetes (T2D). METHODS: A cohort of 939 people with T2D followed prospectively was used to test the performance of risk prediction models developed in Gloucester, UK, and Iceland. Observed risk of progression to RDR in the Irish cohort was compared with that derived from each of the prediction models evaluated. Receiver operating characteristic curves assessed models' performance. RESULTS: The cohort was followed for a total of 2929 person years during which 2906 screening episodes occurred. Among 939 individuals followed, there were 40 referrals (4%) for diabetic maculopathy, pre-proliferative DR and proliferative DR. The original Gloucester model, which includes results of two consecutive retinal screenings; a model incorporating, in addition, systemic biomarkers (HbA1c and serum cholesterol); and a model including results of one retinopathy screening, HbA1c, total cholesterol and duration of diabetes, had acceptable discriminatory power (area under the curve (AUC) of 0.69, 0.76 and 0.77, respectively). The Icelandic model, which combined retinopathy grading, duration and type of diabetes, HbA1c and systolic blood pressure, performed very similarly (AUC of 0.74). CONCLUSION: In an Irish cohort of people with T2D, the prediction models tested had an acceptable performance identifying those at risk of progression to RDR. These risk models would be useful in establishing more personalised screening intervals for people with T2D.
引用
- Smith JJ, Wright DM, Stratton IM, et al. Testing the performance of risk prediction models to determine progression to referable diabetic retinopathy in an Irish type 2 diabetes cohort. Br J Ophthalmol. 2021. PMID: 33903145. doi:10.1136/bjophthalmol-2020-318570
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。